Lead Placement Agent on Aprea Therapeutics’ $30.0 Million Private Placement

Oppenheimer & Co. Inc. acted as a Lead Placement Agent on Aprea Therapeutics’ $30.0 Million Private Placement

Aprea Therapeutics, Inc. (Aprea) (Nasdaq: APRE), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, announced the closing of its previously announced oversubscribed private placement financing. Total gross proceeds from the offering are approximately $30 million to the Company before deducting placement agent fees and other private placement expenses.

The private placement was led by Soleus Capital with participation from other new investors, including Vestal Point Capital and Squadron Capital Management, existing investors and certain insiders of the Company.

In connection with the Offering the Company plans to sell (i) pre-funded warrants to purchase up to an aggregate of approximately 37.2 million shares of common stock (“Pre-Funded Warrants”), for a purchase price equal to $0.808, minus $0.001 per Pre-Funded Warrant, and (ii) warrants to purchase up to an aggregate of approximately 37.2 million shares of common stock.

In addition to the existing biomarker-enriched cohorts under evaluation in the ongoing ACESOT-1051 Phase 1 trial, Aprea plans to use commercially reasonable efforts to seek enrollment of at least 50 patients with uterine serous carcinoma (USC), as well as patients with Cyclin E-overexpressing, platinum-resistant ovarian cancer (PROC) in order to further assess APR-1051 in selected patient populations with high unmet medical need. The Company currently anticipates completing dose escalation of the ACESOT-1051 trial in the second quarter of 2027 and currently expects that the proceeds from the Offering will be sufficient to extend its cash runway into the first quarter of 2028, in each case, based on the Company’s current business plans and assumptions.

Healthcare Life Sciences Investment Banking